Finance

Lists
G1SK34:BVMF
Gsk Plc Bdr
50,50 BRL
0,00%
(0,00) 1D
16-окт., 16:56:00 GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for G1SK34...
Open
50,10 BRL
High
50,75 BRL
Low
50,10 BRL
Mkt. cap
100,21 млд
Avg. vol.
214,00
Volume
165,00
52-wk high
63,24 BRL
52-wk low
46,15 BRL
Shares outstanding
4,32 млд
No. of employees
67 миң
Open
50,10 BRL
High
50,75 BRL
Low
50,10 BRL
Mkt. cap
100,21 млд
Avg. vol.
214,00
Volume
165,00
52-wk high
63,24 BRL
52-wk low
46,15 BRL
Shares outstanding
4,32 млд
No. of employees
67 миң
News stories
From web sources and news partners
The Globe and Mail
The Globe and Mail
·
13 саат мурун
UBS Keeps Their Hold Rating on GlaxoSmithKline (GSK)
JournalArta
JournalArta
·
1 күн мурун
GSK Stock Gains 2.89% on Thursday: Full Details
Yahoo Finance
Yahoo Finance
·
1 күн мурун
Better Dividend Stock: Pfizer vs. GSK
Profile
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England. GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500. The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK. The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
About Gsk Plc Bdr
CEOEmma Walmsley | Emma Walmsley
Employees66,8 миң
Founded2000-ж., 27-дек.
Headquarters-
SectorPharmaceutical industry
Websitegsk.com
Next call 11 күндөн кийин
28-окт., шарш., 14:00
Fiscal period
Q3 2026
- / 0,50 GBP
Revenue / Est. (GBP)
- / 8,81 млд
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in GBP
Loading Previous Earnings...
Revenue
Net income
All values in GBP
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
8,55 млд
8,62 млд
7,63 млд
8,41 млд
Cost of goods sold
2,24 млд
2,62 млд
1,87 млд
2,07 млд
Cost of revenue
2,24 млд
2,62 млд
1,87 млд
2,07 млд
Research and development expenses
1,58 млд
2,14 млд
1,52 млд
1,75 млд
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2,16 млд
2,67 млд
2,08 млд
2,19 млд
Operating expense
3,23 млд
4,37 млд
2,99 млд
3,74 млд
Total operating expenses
5,46 млд
6,99 млд
4,86 млд
5,81 млд
Operating income
3,08 млд
1,63 млд
2,77 млд
2,60 млд
Other non operating income
-
-21,00 млн
-
-
EBT including unusual items
2,46 млд
950,00 млн
2,14 млд
354,00 млн
EBT excluding unusual items
2,94 млд
1,48 млд
2,62 млд
2,48 млд
Income tax expense
312,00 млн
223,00 млн
305,00 млн
-199,00 млн
Effective tax rate
12,70%
23,47%
14,23%
-56,21%
Other operating expenses
-511,00 млн
-434,00 млн
-615,00 млн
-204,00 млн
Net income
2,01 млд
636,00 млн
1,74 млд
435,00 млн
Net profit margin
23,55%
7,38%
22,77%
5,17%
Earnings per share
0,55
-
-
-
Interest and investment income
26,00 млн
17,00 млн
22,00 млн
58,00 млн
Interest expense
-167,00 млн
-145,00 млн
-167,00 млн
-182,00 млн
Net interest expenses
-141,00 млн
-128,00 млн
-145,00 млн
-124,00 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
3,82 млд
2,69 млд
3,23 млд
2,82 млд
Gain or loss from assets sale
-
-40,00 млн
-
-
AI content may include mistakes. Learn more
Google колдонмолору